NuView To Complete 600-Patient in Vitro Double-Blind Clinical Trial

In Clinical Studies News by Barbara Jacoby

NuView will use funds to complete a 600-patient in vitro double-blind clinical trial in accordance with the U.S. Food and Drug Administration (FDA) approval process. NuView will also allocate funds for its in vivo diagnostics and Theranostic programs.

The NV-VPAC1™ test has been successfully utilized for in vitro and in vivo diagnostics detecting multiple types of cancer. In clinical studies, the test showed its ability to accurately detect cancer cells and their location not only inside the body, but outside as well, in voided biofluids, confirming the presence of shed cancer cells. NuView is confident the test has the potential for diagnosing a variety of cancers, transforming patient care. The GEM endorsement greatly expedites the process towards potential commercialization.

With this agreement, a revolutionary cancer diagnostic tool and treatment comes closer to market availability.

  • Almost 5,000 people every day in the United States are diagnosed with cancer.
  • 1,662 people die each day of cancer in the United States.
  • NuView’s Theranostics Application, utilizing proprietary VPAC1™ technology, combines and simultaneously delivers one radioactive drug to identify (diagnose and localize) cancer cells, and a second radioactive drug to deliver therapy to treat the cells constituting the primary tumor and any metastatic tumors.

“This agreement with GEM helps to secure the funding for continued growth and development of NuView’s NV-VPAC1Ô portfolio. As we focus on moving our in vitro cancer diagnostics into the marketplace, we can simultaneously restart our in vivo diagnostics and Theranostic programs forward,” stated Paul Crowe, Chairman and CEO of NuView.

About The GEM Group:
Global Emerging Markets is a $3.4 billion, alternative investment group with operations in Paris, New York, and Los Angeles. GEM manages a diverse set of investment vehicles focused on emerging markets that provide the group and its investors with a diversified portfolio of asset classes that span the global private investing spectrum. Each investment vehicle has a different degree of operational control, risk-adjusted return, and liquidity profile. The family of funds and investment vehicles provide GEM and its partners with exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities and select venture investments. For more information:

About NuView Life Sciences, Inc.:
NuView Life Sciences, located in Park City, UT, is an innovative, clinical stage, precision oncology company. NuView’s mission is to change the way cancer is currently diagnosed and treated. The earlier cancer is identified, the better the treatment options are and the greater the chances for successful outcomes. To learn more about NuView Life Sciences, please visit